Research Article
Do Increased Doses to Stem-Cell Niches during Radiation Therapy Improve Glioblastoma Survival?
Table 1
Patient characteristics. Numbers in brackets represent percentages and refer to the absolute values in front.
| | Cofactors | All
= 65 | Conventionally fractionated patients
= 54 | Average IL SVZ dose ≥ 40 Gy
= 31 | Average IL SVZ dose < 40 Gy
= 23 | Average CL SVZ dose ≥ 30 Gy
= 12 | Average CL SVZ dose < 30 Gy
= 42 |
| | Gender | | | | | | | | Male | 43 (66.2) | 38 (70.4) | 21 (67.7) | 17 (73.9) | 8 (66.7) | 34 (81.0) | | Female | 22 (33.8) | 16 (29.4) | 10 (32.3) | 6 (26.1) | 4 (33.3) | 8 (19.0) |
| | Median age in years (range) | 58.9 (29.5–78.3) | 55.1 (29.5–78.3) | 53.8 (39.7–75.5) | 59.1 (29.5–77.8) | 53.6 (40.8–73.4) | 56.2 (29.5–77.8) | | Median Karnofsky performance status in % (range) | 90 (60–100) | 90 (70–100) | 90 (70–100) | 90 (70–100) | 90 (70–100) | 90 (70–100) |
| | Peripheral | 32 (49.2) | 27 (50) | 15 (48.4) | 12 (52.2) | 6 (50.0) | 21 (50.0) | | Central | 33 (50.8) | 27 (50) | 16 (51.6) | 11 (47.8) | 6 (50.0) | 21 (50.0) |
| | MGMT promoter methylated | 14 (21.5) | 14 (25.9) | 7 (22.6) | 7 (30.4) | 3 (25.0) | 11 (26.2) | | MGMT promoter not methylated | 17 (26.2) | 14 (25.9) | 11 (35.5) | 3 (13.0) | 3 (25.0) | 11 (26.2) | | MGMT not determined | 34 (52.3) | 26 (48.2) | 13 (41.9) | 13 (56.5) | 6 (50.0) | 20 (47.6) |
| | Surgical resection | 56 (86.2) | 46 (85.2) | 27 (87.1) | 19 (82.6) | 9 (75.0) | 22 (52.4) | | Gross total resection | 26 (40.0) | 20 (37.0) | 10 (32.2) | 10 (43.5) | 3 (25.0) | 11 (26.2) | | Subtotal resection | 30 (46.2) | 26 (48.1) | 17 (54.8) | 9 (39.1) | 6 (50.0) | 11 (26.2) | | Biopsy | 8 (12.3) | 7 (13.0) | 4 (12.9) | 3 (13.0) | 3 (25.0) | 20 (47.6) | | n.d. | 1 (1.5) | 1 (1.9) | 0 (0) | 1 (4.3) | 0 (0) | 1 (2.4) |
| | Volume of PTV in mL (range) | 342.0 (117.4–674.7) | 280.6 (117.4–674.7) | 377 (177.8–674.74) | 266 (117.4–520.8) | 401.3 (265.2–674.7) | 324.3 (117.4–560.6) | | Median total dose in Gy (range) | 60.0 (40.05–68) | 60.0 (59.4–68) | 60.0 (59.4–60) | 60.0 (59.4–68) | 60.0 (59.4–60) | 60.0 (59.4–68) | | Median single dose in Gy (range) | 2.0 (1.8–2.67) | 2.0 (1.8–2.0) | 2.0 (1.8–2.0) | 2.0 (1.8–2.0) | 2.0 (1.8–2.0) | 2.0 (1.8–2.0) |
|
|
Gy: gray; MGMT: O-6-methylguanine methyltransferase; IL: Ipsilateral; CL: contralateral; SVZ: subventricular zone; PTV: planning target volume; n.d.: not determined.
|
